ClinicalTrials.gov

History of Changes for Study: NCT02963168
A DRF Study to Evaluate Safety, Tolerability, PK, and Activity of Oradoxel Monotherapy in Subjects w Adv. Malignancies
Latest version (submitted October 15, 2019) on ClinicalTrials.gov
  • A study version is represented by a row in the table.
  • Select two study versions to compare. One each from columns A and B.
  • Choose either the "Merged" or "Side-by-Side" comparison format to specify how the two study versions are to be displayed. The Side-by-Side format only applies to the Protocol section of the study.
  • Click "Compare" to do the comparison and show the differences.
  • Select a version's Submitted Date link to see a rendering of the study for that version.
  • The yellow A/B choices in the table indicate the study versions currently compared below. A yellow table row indicates the study version currently being viewed.
  • Hover over the "Recruitment Status" to see how the study's recruitment status changed.
  • Study edits or deletions are displayed in red.
  • Study additions are displayed in green.
Study Record Versions
Version A B Submitted Date Changes
1 November 9, 2016 None (earliest Version on record)
2 May 12, 2017 Recruitment Status, Contacts/Locations, Study Status, Arms and Interventions, Oversight and Study Design
3 March 2, 2018 Contacts/Locations and Study Status
4 January 8, 2019 Contacts/Locations, Sponsor/Collaborators, Study Status and Study Identification
5 October 15, 2019 Recruitment Status and Study Status
Comparison Format:

Scroll up to access the controls

Study NCT02963168
Submitted Date:  November 9, 2016 (v1)

Open or close this module Study Identification
Unique Protocol ID: KX-ORADOX-003
Brief Title: A DRF Study to Evaluate Safety, Tolerability, PK, and Activity of Oradoxel Monotherapy in Subjects w Adv. Malignancies
Official Title: A Dose Regimen-Finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Activity of Oradoxel Monotherapy in Subjects With Advanced Malignancies
Secondary IDs:
Open or close this module Study Status
Record Verification: November 2016
Overall Status: Not yet recruiting
Study Start: December 2016
Primary Completion: December 2018 [Anticipated]
Study Completion: December 2019 [Anticipated]
First Submitted: October 7, 2016
First Submitted that
Met QC Criteria:
November 9, 2016
First Posted: November 15, 2016 [Estimate]
Last Update Submitted that
Met QC Criteria:
November 9, 2016
Last Update Posted: November 15, 2016 [Estimate]
Open or close this module Sponsor/Collaborators
Sponsor: Kinex Pharmaceuticals Inc.
Responsible Party: Sponsor
Collaborators:
Open or close this module Oversight
U.S. FDA-regulated Drug:
U.S. FDA-regulated Device:
Data Monitoring: No
Open or close this module Study Description
Brief Summary: This is a nonrandomized, open-label, dose escalation, safety, activity, and PK study to determine the MTD and optimal dosing regimen of Oradoxel. No control group has been included.
Detailed Description:

This is a multicenter, open-label, safety, tolerability, pharmacokinetic, and activity study. Eligible subjects will be adults with advanced solid malignancies.

Groups of 3 to 6 subjects will receive a single dose of Oradoxel and will be followed for toxicity. If non linearity in PK is observed, additional subjects will receive Oradoxel as 2 single daily doses once every three weeks. Subjects who tolerate the drug and have stable disease or better response will be eligible to receive ongoing treatment.

Open or close this module Conditions
Conditions: Solid Tumor
Keywords:
Open or close this module Study Design
Study Type: Interventional
Primary Purpose: Treatment
Study Phase: Phase 1
Interventional Study Model: Single Group Assignment
Number of Arms: 2
Masking: None (Open Label)
Allocation: Non-Randomized
Enrollment: 24 [Anticipated]
Open or close this module Arms and Interventions
Arms Assigned Interventions
Experimental: Oradoxel - Part 1
To determine the MTD of Oradoxel (oral docetaxel and oral HM30181A) when administered once every 3 weeks.
Drug: Oradoxel
oral docetaxel + oral HM30181A
Experimental: Oradoxel - Part 2
To determine the MTD of Oradoxel (oral docetaxel and oral HM30181A) when administered for two days every three weeks.
Drug: Oradoxel
oral docetaxel + oral HM30181A
Open or close this module Outcome Measures
Primary Outcome Measures:
1. The maximum tolerated dose (MTD) of Oradoxel based on dose-limiting toxicity (DLT) in subjects with advanced malignancies
[ Time Frame: 3 weeks ]

The MTD will be the highest dose at which no more than 1 of 6 subjects experience a DLT during treatment and Oradoxel pharmacokinetics are acceptable.
Secondary Outcome Measures:
1. Safety assessment using AEs of Oradoxel
[ Time Frame: Weekly, up to 24 months ]

2. Safety assessment using SAEs of Oradoxel
[ Time Frame: Weekly, up to 24 months ]

3. Laboratory evaluation for hematology
[ Time Frame: Weekly, up to 24 months ]

4. Blood chemistry
[ Time Frame: Weekly, up to 24 months ]

5. Urine analysis
[ Time Frame: Weekly, up to 24 months ]

6. Periodic measurements of ECGs
[ Time Frame: Screening, Day 1, every 6 weeks thereafter up to 24 months ]

7. Periodic measurements of vital signs
[ Time Frame: Weekly, up to 24 months ]

8. The incidence of unacceptable toxicity with Oradoxel
[ Time Frame: 24 months ]

Unacceptable toxicity graded according to CTCAE v4.03
9. The recommended Phase 2 dose (RP2D) of Oradoxel
[ Time Frame: 24 months ]

Upon determination of the overall MTD for Oradoxel, the safety and PK profile of the study treatment from all Treatment Periods will be reviewed to determine the recommended Phase 2 dose.
10. The amount of docetaxel and HM30181A in blood stream by Area under the plasma concentration versus time curve (AUC)
[ Time Frame: Part 1: 16 timepoints over 504 hours; Part 2: 26 timepoints over 480 hours ]

11. The peak plasma concentration (Cmax) and Minimum plasma concentration (Cmin)
[ Time Frame: Part 1: 16 timepoints over 504 hours; Part 2: 26 timepoints over 480 hours ]

12. A biological half-life or elimination half-life (t1/2)
[ Time Frame: Part 1: 16 timepoints over 504 hours; Part 2: 26 timepoints over 480 hours ]

13. The accumulation ratio (R)
[ Time Frame: Part 1: 16 timepoints over 504 hours; Part 2: 26 timepoints over 480 hours ]

14. The apparent total clearance of the drug from plasma (CL/F)
[ Time Frame: Part 1: 16 timepoints over 504 hours; Part 2: 26 timepoints over 480 hours ]

15. The apparent volume of distribution (Vd/F)
[ Time Frame: Part 1: 16 timepoints over 504 hours; Part 2: 26 timepoints over 480 hours ]

16. To evaluate tumor response
[ Time Frame: Every 12 weeks, up to 24 months ]

Tumor response will be evaluated according to RECIST v1.1
Open or close this module Eligibility
Minimum Age: 18 Years
Maximum Age:
Sex: All
Gender Based:
Accepts Healthy Volunteers: No
Criteria:

Inclusion Criteria:

  1. Signed written informed consent
  2. ≥18 years of age
  3. Histologically or cytologically confirmed solid tumor that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective
  4. Docetaxel monotherapy is a reasonable treatment in the judgement of the Investigator
  5. Measurable disease as per RECIST v1.1 criteria
  6. Able to swallow oral medication as an intact dosage form
  7. Adequate hematologic status as demonstrated by not requiring transfusion support or granulocyte-colony stimulating factor (G-CSF) to maintain: Absolute neutrophil count (ANC) ≥1500 cells/mm3, Platelet count ≥100 x 109/L, Hemoglobin (Hgb) ≥10 g/dL
  8. Adequate liver function as demonstrated by: Total bilirubin of < upper limit of normal (ULN), Aspartate transaminase (AST) and alanine aminotransferase (ALT) ≤1.5 × ULN, Alkaline phosphatase (ALP) ≤2.5x ULN or <5x ULN if bone metastases are present, Normal serum albumin
  9. Adequate renal function as demonstrated by serum creatinine ≤1.5 x ULN or creatinine clearance>60 mL/min as calculated by the Cockroft and Gault formula
  10. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1
  11. Life expectancy of at least 3 months
  12. Willing to fast for 6 hours before and 2 hours after Oradoxel administration
  13. Females must be postmenopausal (>12 months without menses) or surgically sterile (ie, by hysterectomy and/or bilateral oophorectomy) or, if sexually active, must be using effective contraception (ie, oral contraceptives, intrauterine device, double barrier method of condom and spermicide) and agree to continue use of contraception for 30 days after their last dose of study drug.
  14. Sexually active male subjects must use a barrier method of contraception during the study and agree to continue the use of male contraception for at least 30 days after the last dose of study drug.

Exclusion Criteria:

  1. Currently taking a prohibited concomitant medication, other than a premedication, that are/is:
    • Strong inhibitors (eg, ketoconazole) or inducers (eg, rifampicin or St. John's Wort) of CYP3A4 (within 2 weeks prior to the start of dosing in the study)
    • Strong P-gp inhibitors or inducers. Subjects who are taking such medications but who are otherwise eligible may be enrolled if they discontinue the medication ≥1 week before dosing and remain off that medication through the end of PK sampling after the administration of the second study treatment
    • An oral medication with a narrow therapeutic index known to be a P-gp substrate within 24 hours prior to start of dosing in the study
  2. Unresolved toxicity from prior chemotherapy (subjects must be recovered to ≤ Grade 1 toxicity from previous anticancer treatments or previous investigational products.
  3. Planning to receive other medical, surgical, or radiological cancer treatments during the course of this study
  4. Received investigational agents within 14 days or 5 half-lives prior to the first study dosing day, whichever is longer
  5. Require therapeutic use of anticoagulants
  6. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, clinically significant myocardial infarction within the last 6 months, unstable angina pectoris, clinically significant cardiac arrhythmia, bleeding disorder, chronic pulmonary disease requiring oxygen, or psychiatric illness/social situations that would limit compliance with study requirements
  7. Major surgery to the upper gastrointestinal (GI) tract, or have a history of GI disease or other medical condition that, in the opinion of the Investigator, may interfere with oral drug absorption
  8. A known history of allergy to docetaxel, Cremophor or polysorbate 80 (Tween 80)
  9. Evidence of fluid retention at Screening (including, for example, peripheral edema, pleural effusion, or ascites on physical or radiological examination) or history of severe capillary leak syndrome
  10. Any other condition which the Investigator believes would make participation in the study not acceptable
Open or close this module Contacts/Locations
Central Contact Person: E. Douglas Kramer, MD
Telephone: 908-272-0628
Email: dkramer@kinexpharma.com
Central Contact Backup: Ildiko Bezi
Telephone: 908-272-0628
Email: ibezi@kinexpharma.com
Study Officials: E. Douglas Kramer, MD
Study Director
Kinex Pharmaceuticals Inc.
Locations: United States, Texas
UT Health Science Center at San Antonio
San Antonio, Texas, United States, 78229
Open or close this module IPDSharing
Plan to Share IPD: No
Open or close this module References
Citations:
Links:
Available IPD/Information:

Scroll up to access the controls Scroll to the Study top

U.S. National Library of Medicine | U.S. National Institutes of Health | U.S. Department of Health & Human Services